Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vincristine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 0.97 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 0.97 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 0.97 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 0.97 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 0.97 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 0.97 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 0.97 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 0.97 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 0.97 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 0.97 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 0.97 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 0.97 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 0.97 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 0.97 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 0.97 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vincristine SCHEMBL3998 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL4640472 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL4709855 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL2946485 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL18398051 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL3710 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL29519343 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL4742962 | 0.99 | MAPT (0.98) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL18402663 | 0.98 | LMNA (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL4769981 | 0.98 | LMNA (1.00) | MAPTMEN1KMT2ALMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4203950-B1 | COMBINATIONS OF A DHODH INHIBITOR AND R-CHOP THERAPY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA AND BURKITT LYMPHOMA | SERVIER LAB (FR) | 2026-02-18 | — | — | EP | claimed |
| EP-4014047-B1 | OGDH INHIBITORS FOR USE IN THE TREATMENT OF CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-11-19 | — | — | EP | claimed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | claimed |
| EP-3180349-B1 | LYMPH DIRECTING PRODRUGS AND THERAPEUTIC USES THEREOF | UNIV MONASH (AU) | 2025-03-12 | — | — | EP | claimed |
| EP-4086250-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-12-11 | — | — | EP | claimed |
| EP-4244394-B1 | TECHNIQUES FOR IDENTIFYING FOLLICULAR LYMPHOMA TYPES | BOSTONGENE CORP (US) | 2024-06-19 | — | — | EP | claimed |
| EP-3886875-B1 | METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS INC (US) | 2024-05-08 | — | — | EP | claimed |
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| EP-3337456-B1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SHANGHAI GINPOSOME PHARMATECH CO LTD (CN) | 2022-10-26 | — | — | EP | claimed |
| US-20220409560-A1 | Pharmaceutical Compositions, Formulations And Methods For The Treatment Of Retinoblastoma | OXULAR LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| CN-115209898-A | Pharmaceutical composition and preparation for treating retinoblastoma | 奥叙拉尔有限公司 | 2022-10-18 | — | — | CN | disclosed |
| EP-4065118-A2 | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS FOR THE TREATMENT OF RETINOBLASTOMA | Oxular Limited (GB) | 2022-10-05 | — | — | EP | disclosed |